Pletal
(cilostazol)ApprovedSmall molecule
OtsukaCilostazol is used to improve walking distance in people with a painful leg condition called intermittent claudication, which is caused by poor blood circulation in the legs.[2] Pletal is currently approved and in use across 37 indications[4].[1]
Pletal is one of 603 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.
37
Indications
115
Total Trials
22
Active Trials
602
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 34 indications
Competition
Competitive Landscape
198 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Pletal
OtsukaApproved
Bayer Aspirin
BayerPreclinical
Amidate
PfizerPreclinical
Brethine
SanofiPreclinical
Medrol
PfizerPreclinical
Adriamycin
PfizerPreclinical
Savaysa
Daiichi SankyoPreclinical
Activase
RochePreclinical
Zemplar
AbbViePreclinical
Xifaxan
SSalix
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Stroke10 trials
CiLostAzol for pReventIon of Recurrent sTroke in Africa
Not yet recruiting·NNorthern California Institute of Research and Education·Phase 3·NCT06919835·1,100 enrolled
Show 7 more trials
Ischemic stroke8 trials
Show 5 more trials
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Unknown status·—·Phase 4·NCT01013532·1,600 enrolled
PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study
Unknown status·—·Phase 4·NCT02483169·800 enrolled
Fasting Conditions6 trials
Headache5 trials
MPA5 trials
59 more indications
Trial4 trials
Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II
Completed·—·Phase 4·NCT00130039·457 enrolled
Show 1 more trial
Dual Antiplatelet Therapy3 trials
Atherosclerosis3 trials
The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis
Recruiting·—·Phase 4·NCT06757764·2,340 enrolled
Treatment2 trials
Sufficient Treatment of Peripheral Intervention by Cilostazol
Unknown status·—·Phase 4·NCT00912756·200 enrolled
ART2 trials
Cerebral Small Vessel Disease2 trials
Peripheral Arterial Disease2 trials
Clopidogrel2 trials
Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients
Completed·—·N/A·NCT01779401·1,078 enrolled
Rheumatoid Arthritis2 trials
The Effect of Cilostazol on Rheumatoid Arthritis Patients
Completed·—·Phase 2/3·NCT05671497·70 enrolled
Cognitive impairment2 trials
Subarachnoid Hemorrhage2 trials
Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage
Not yet recruiting·—·Phase 3·NCT07144956·630 enrolled
TED2 trials
Migraine2 trials
Interaction2 trials
Cilostazol-Simvastatin Drug Interaction Study
Unknown status·—·Phase 1·NCT02431013·20 enrolled
Resistance1 trial
Overcome Biochemical Aspirin Resistance Through Cilostazol Combination
Completed·—·Phase 4·NCT00446641·244 enrolled
Platelet Aggregation1 trial
Diabetic Foot1 trial
Impact of Cilostazol Versus Cilostazol and Selenium Combination on the Healing of Diabetic Foot Ulcer Patients
Completed·—·Phase 2/3·NCT06117436·206 enrolled
Coronary Artery Disease1 trial
Genetic Polymorphism1 trial
Cardiovascular Disease1 trial
Acute1 trial
Peripheral Vascular Disease1 trial
Drug Repurposing1 trial
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Pentoxifylline Versus Cilostazol
Completed·—··NCT05635370·10,398 enrolled
Cerebral Infarction1 trial
Aneurysm1 trial
Diabetic Nephropathy1 trial
The Use of Cilostazol in Patients With Diabetic Nephropathy
Completed·—·Phase 4·NCT00272831·62 enrolled
Platelet Inhibition1 trial
Exercise1 trial
Claudication: Exercise Versus Endoluminal Revascularization (CLEVER)
Unknown status·—·Phase 3·NCT00132743·119 enrolled
Acute Myocardial Infarction1 trial
Heart Disease1 trial
Major Depressive Disorder1 trial
Cerebral ischemia1 trial
The Effect of Cilostazol Compared to Aspirin on Endothelial Function in Acute Cerebral Ischemia Patients
Completed·—·Phase 4·NCT03116269·80 enrolled
Intermittent Claudication1 trial
Fatty Liver Disease1 trial
Osteoarthritis1 trial
Percutaneous Coronary Intervention1 trial
Vascular Dementia1 trial
Plaque1 trial
Efficacy and Safety1 trial
Parkinson1 trial
Cilostazol in Parkinson's Disease
Not yet recruiting·—·Phase 2·NCT06612593·50 enrolled
Antithrombotic Agents1 trial
OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial
Completed·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT01955200·1,724 enrolled
Diabetes Mellitus1 trial
Multiple Sclerosis1 trial
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT03109288·250 enrolled
Cervical Carcinoma1 trial
Cerebral Small Vessel Diseases1 trial
Unspecified5 trials
Cilostazol Following Peripheral Endovascular Procedures
Unknown status·—·Phase 3·NCT02770274·200 enrolled
Regulatory
FDA Approval Timeline[5]
Jan 15, 1999
PLETAL
NDA NDA020863
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Pletal drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for cilostazol. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]